Despite risk-adapted treatment, survival of children with relapse of acute lymphoblastic leukemia (ALL) remains poor compared with that of patients with initial diagnosis of ALL. Leukemia-associated genetic alterations may provide novel prognostic factors to refine present relapse treatment strategies. Therefore, we investigated the clinical relevance of 13 recurrent genetic alterations in 204 children treated uniformly for relapsed B-cell precursor ALL according to the ALL-REZ BFM 2002 protocol. The most common alterations were deletions of CDKN2A/2B, IKZF1, PAX5, ETV6, fusion of ETV6-RUNX1 and deletions and/or mutations of TP53. Multivariate analysis identified IKZF1 deletion and TP53 alteration as independent predictors of inferior outcome (P ¼ 0.002 and P ¼ 0.001). Next, we investigated how both alterations can improve the established risk stratification in relapsed ALL. Intermediate-risk relapse patients with low minimal residual disease are currently considered to have a good prognosis. In this group, deletion of IKZF1 and alteration of TP53 identify patients with significantly inferior outcome (Po0.001). In high-risk relapse patients, deletion of IKZF1 is strongly predictive of a second relapse after stem cell transplantation (Po0.001). We conclude that IKZF1 and TP53 represent relevant prognostic factors that should be considered in future risk assessment of children with relapsed ALL to indicate treatment intensification or intervention.
INTRODUCTION
In childhood acute lymphoblastic leukemia (ALL), B20% of patients suffer a relapse. 1 Children with relapsed ALL generally receive a more intense therapy compared with children with initial diagnosis of ALL; still, long-term outcome after relapse remains unsatisfactory with cure rates of merely 30-40%. [2] [3] [4] The German Berlin-Frankfurt-Mü nster study group on relapsed ALL (ALL-REZ BFM) aims at optimising risk-adapted treatment strategies for children with ALL relapse. In the current ALL-REZ BFM 2002 protocol, the intensity of chemotherapy and the allocation of patients to hematopoietic stem cell transplantation (HSCT) are based on clinical prognostic factors, that is, the time to relapse relative to primary treatment, the site of relapse and the immunophenotype. An early recurrence of the disease (o6 months after completion of primary treatment), bone marrow (BM) involvement, and T-cell immunophenotype are associated with inferior outcome. [5] [6] [7] A combination of these prognostic factors is used to stratify relapse patients into a standard-risk (S1), intermediate-risk (S2) and high-risk group (S3/S4). After a common intensive induction therapy, these groups are allocated to different treatment regimens that consist of multi-agent chemotherapy and radiation therapy if necessary. Further treatment intensification by HSCT is required for high-risk (S3/ S4) patients given that a second complete remission (CR2) can be induced. HSCT is also indicated for intermediate-risk (S2) patients with high levels of minimal residual disease (MRD) at the end of the induction therapy (week 5) , that is, a burden of 1 or more leukemic cells in 1000 normal cells (X10 À 3 ). 8 Despite this risk-adapted treatment, a substantial number of children with relapsed ALL still suffer a subsequent event, even in subgroups that present clinically with features of low risk. Therefore, an early and accurate identification of relapse patients at high risk of therapy failure is essential to further adapt and improve treatment intensification and intervention strategies. Leukemia-associated genetic alterations may provide novel prognostic tools to refine the risk assessment of children with ALL relapse. In the treatment of children with initial diagnosis of ALL, recurrent chromosomal translocations leading to the fusion genes BCR-ABL1, MLL-AFF1 or ETV6-RUNX1 are established prognostic factors used for risk stratification of patients. [9] [10] [11] [12] [13] [14] Furthermore, genome-wide analyses in B-cell precursor (BCP)-ALL discovered frequent copy number alterations in genes either involved in lymphoid development (for example, EBF1, PAX5, IKZF1) or in cell cycle regulation (for example, CDKN2A, CDKN2B, RB1). [15] [16] [17] [18] Another recurrent deletion affecting the genes CSF2RA, IL3RA and P2RY8 was identified in the pseudoautosomal region 1 (PAR1) of the sex chromosomes, leading to a fusion of the P2RY8 and CRLF2 gene (P2RY8-CRLF2). 19, 20 Of these copy number alterations, particularly IKZF1 and PAR1 deletions have been associated with poor outcome after primary treatment of children with ALL.
In children with relapsed ALL, much less in-depth knowledge is available on the frequency and the prognostic value of genetic alterations. In previous studies of relapsed ALL, ETV6-RUNX1 has been associated with a favourable and BCR-ABL1 with an adverse prognosis. [28] [29] [30] In contrast, deletions of CDKN2A/2B did not affect the outcome after relapse treatment at all. 31 However, these analyses were based on heterogeneous patient cohorts enrolled in different ALL-REZ BFM trials. Hence, the aim of our current study was to systematically explore the value of leukemia-associated genetic alterations as prognostic factors in relapsed ALL in a single trial setting. Therefore, we studied the frequency and clinical relevance of 13 genetic alterations in 204 children with first BM relapse of BCP-ALL who were treated uniformly according to the current ALL-REZ BFM 2002 relapse protocol.
Specifically, we investigated copy number alterations of EBF1, IKZF1, CDKN2A, CDKN2B, PAX5, ETV6, BTG1, RB1 and the PAR1 region as well as fusion genes ETV6-RUNX1, BCR-ABL1 and MLL-AFF1. Furthermore, we integrated in this study the information on mutations and deletions of the TP53 gene (collectively termed TP53 alterations) from a previous report, in which we described a high correlation between TP53 alteration and treatment failure after ALL relapse. 32 Our present study shows that deletion of IKZF1 and alteration of TP53 are independent predictors of poor outcome after ALL relapse. Therefore, we suggest to integrate these genetic factors in future risk assessment of children with relapsed ALL to improve riskadapted treatment strategies.
MATERIALS AND METHODS

Patients and samples
All patients were enrolled in the German multi-center randomised trial ALL-REZ BFM 2002 (NCT00114348) approved by the local ethics committee. Written informed consent was obtained from patients or guardians. Patients were selected for the study if they had a first isolated or combined BM relapse of BCP-ALL, if they were treated according to the trial protocol, and if high-quality DNA and RNA from relapse diagnosis were available. The selected cohort included eight patients with Down's syndrome who were treated according to the trial protocol without deviations. For details on risk stratification and treatment of patients see the Supplementary Materials and Methods. The median percentage of leukemic blasts in BM or peripheral blood samples from relapse diagnosis was 90% at the time of sample collection (minimum, 19%; maximum, 99%; Supplementary Figure 1) . Before any further analysis, all BM or peripheral blood samples were enriched for mononuclear cells (MNC) by ficoll density gradient centrifugation. DNA was purified from MNCs using the Gentra Puregene Cell Kit (Qiagen, Hilden, Germany). RNA was isolated from MNCs using the Qiagen RNeasy Mini Kit with DNase digestion and including homogenisation by QIAshredder (Qiagen).
Detection of copy number alterations
The copy number status of EBF1, IKZF1, CDKN2A, CDKN2B, PAX5, ETV6, BTG1, RB1, and of CSF2RA, IL3RA, P2RY8 (PAR1 deletion) was analysed by multiplex ligation-dependent probe amplification (MLPA), using the probe set P335 'ALL-IKZF1' from MRC-Holland (Amsterdam, The Netherlands), according to the manufacturer's instructions. The probe targeted to P2RY8 exon 2 was a synthetic MLPA oligo pair that we designed according to the guidelines of MRC-Holland. We added this probe to the kit to enhance the detection of a PAR1 deletion (5 0 -TGTTTGCGTAAAAGGCCACGGTCACCACGT TGCAATCTAGATTGGATCTTGCTGGCAC-3 0 ; 5 0 -GGGTTCCCTAAGGGTTGGAGC TGATACAGGTCATGGTGAGGATGCTGGAATACA-3 0 ; length of amplification product: 112 nucleotides). MLPA amplification products were separated and quantified by capillary electrophoresis using an ABI 3730 DNA Analyzer with GeneScan 500 LIZ as internal size standard (both Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA). DNA fragment analysis and peak sizing was carried out with ABI Peak Scanner Software v1.0 (Applied Biosystems, Life Technologies Corporation). Data were normalised using the Coffalyser MLPA-DAT software provided by MRC-Holland (Amsterdam, The Netherlands). Six DNA samples from MNCs either of healthy blood donors or of BM samples from ALL relapse patients with an isolated extramedullary relapse were run as references in each experiment. A gene was considered to contain a deletion if at least one MLPA probe targeted to this gene showed a copy number loss.
Sensitivity and specificity of MLPA data
To test the sensitivity of the MLPA method, we performed serial dilution experiments by titrating DNA from the leukemic cell line MHH-cALL2 with DNA from healthy donors. The cell line showed a homozygous loss of CDKN2A/2B and trisomy of all X-chromosome targeted MLPA probes of the P335 'ALL-IKZF1' kit. In consistence with Schwab et al., 33 we observed a detection limit of the MLPA method at 20% of abnormal DNA. The majority of analysed leukemic samples (156/204) had a blast percentage of X80% before enrichment of MNC by Ficoll gradient centrifugation. However, in five cases the percentage of blasts was between 19 and 30% at sample collection and before enrichment. We were able to detect genetic alterations by MLPA in samples with blast percentages as low as 19, 24 and 25%. Only two samples below 50% (21 and 28%) were fully negative with the P335 MLPA kit (Supplementary Figure 1) . To test the specificity of the MLPA method, we confirmed the MLPA results by copy number data derived from SNP 6.0 microarrays (Affymetrix, Santa Clara, CA, USA) available from 14 leukemic samples of the studied patients (2 BM samples from initial diagnosis, 12 BM samples from relapse diagnosis). For EBF1, IKZF1, CDKN2A, CDKN2B, PAX5, ETV6, RB1 and P2RY8, we found a perfect match of MLPA and microarray-derived data (Supplementary Table 1 ). Only one patient with a PAX5 deletion had a discordant result for PAX5 exon 10, whereas PAX5 exons 6 and 8 were shown to be deleted using both the methods. Thus, our data confirms the reliability of the P335 'ALL-IKZF1' kit described by Schwab et al. 33 Validation of the copy number status for BTG1, CSF2R and IL3R was not possible because these genes were insufficiently covered by the 6.0 SNP array. For patients with a deletion of CSF2R, IL3R and P2RY8 (PAR1 deletion), we further confirmed the presence of the resulting fusion gene P2RY8-CRLF2 by reverse transcriptase PCR (RT-PCR). Total RNA was available from 12 of the 13 patients with the PAR1 deletion. A total of 1 mg was reverse transcribed using random priming and SuperScript II Reverse Transcriptase in a final volume of 20 ml according to the manufacturer's instructions (Invitrogen, Darmstadt, Germany). A total of 1 ml of the RT reaction was used for subsequent PCR amplification of the fusion gene with primers located in P2RY8 exon 1 (forward) and CRLF2 exon 3 (reverse) described by Cario et al. 22 
Detection of translocation-associated fusion genes
Fusion genes ETV6-RUNX1, MLL-AFF1 and BCR-ABL1 were detected by RT-PCR. The RT reaction was carried out as described above. A total of 1 ml of cDNA was used for subsequent PCR amplification at 65 1C universal annealing temperature. ABL1 was amplified to control for RNA integrity. ETV6-RUNX1, and minor and major BCR-ABL1 were detected in duplicate by real-time semi-quantitative PCR using serial dilutions of RNA from fusion gene-positive cell lines REH, TOM-1 and K562 in RNA derived from MNCs of healthy volunteers as standard. MLL-AFF1 was amplified by conventional nested PCR using a 10 À 3 dilution of RNA from the cell line SEM as sensitivity control. Primers and probes are given in Supplementary Table 2.
Statistical analysis
Equality of categorical and continuous variables was analysed by Pearson's w 2 or Fisher's exact test and by Mann-Whitney U or Kruskal-Wallis test, respectively. Probabilities of event-free (pEFS) and overall survival (pOS) were estimated by Kaplan-Meier analyses and differences were compared with a log-rank test. EFS time was defined as time between relapse diagnosis and the date of analysis or a subsequent event (second relapse, secondary malignancy or death in CR). In case of death during induction or non-response to chemotherapy, EFS time was set to zero. OS time was defined as time from relapse diagnosis to death or for surviving patients to the date of analysis. The cumulative incidence of relapse (CIR) was analysed according to Kalbfleisch and Prentice, and differences were compared using Gray statistics. Multivariate Cox regression modelling was done for EFS using backward stepwise selection to remove non-significant factors. Statistical calculations were performed using SPSS PASW 18.0.1 software for Windows (SPSS Inc., Chicago, IL, USA). For CIR statistics, the R package cmprsk of the R software v2.10.1 was used. 34 Genetics of relapsed childhood B-cell precursor ALL S Krentz et al
RESULTS AND DISCUSSION
Characteristics of the studied patients We assessed the prognostic value of 13 genetic alterations in 204 patients with first isolated or combined BM relapse of B-cell precursor (BCP) ALL. Bone marrow relapses of BCP origin characterise the majority (70-75%) of all patients enrolled in the current ALL-REZ BFM trial. Relapse of T-cell ALL is observed in only 10-15% of patients and was not considered in our study as it constitutes a distinct leukemia subtype with a different pattern of genetic alterations. 35, 36 In addition, the minor subgroup of isolated extramedullary relapses (10-15% of all patients, ALL-REZ BFM 2002 standard-risk group S1 and partially intermediate-risk group S2) was excluded from our investigation due to an insufficient number of extramedullary specimen. Altogether, our study includes more than half of all BCP-ALL patients with a first BM relapse (204/343, 59%) enrolled in the current ALL-REZ BFM 2002 trial within a 7-year-period (between 2002 and 2009). We observed no selection bias regarding clinical, biological and treatment parameters (Supplementary Table 3 ). All relapse patients were treated uniformly according to the trial protocol and the surviving patients had a mean follow-up time of 4.4 years (median, 4.2 years; range 1.5-8.4 years) enabling appropriate survival analysis. Our study covers the most common genetic alterations in childhood ALL; however, cytogenetic information on, for example, ploidy could not be included due to a lack of routine karyotyping in the ALL-REZ BFM 2002 trial. Still, to the best of our knowledge, the present study represents the most comprehensive analysis so far on the frequency and prognostic value of genetic alterations in relapsed childhood BCP-ALL.
Frequency of genetic alterations in children with first BM relapse of BCP-ALL The most common genetic alterations were deletions of CDKN2B (37.7%), CDKN2A (37.3%), IKZF1 (33.3%), PAX5 (26.5%), ETV6 (25%), fusion of ETV6-RUNX1 (15.2%) and alterations of TP53 (11.3%; Figure 1a ). All other genetic alterations that we investigated, that is, deletions of BTG1, RB1 and EBF1, as well as amplifications of PAX5 and fusion genes P2RY8-CRLF2, MLL-AFF1 and BCR-ABL1, were present in less than 10% of the patients (Figure 1a ). 37.3%
% of all patients (n=204) Other boxes indicate the number of patients sharing two particular alterations. Blue or red color indicates a significant overlap or exclusion, respectively. Owing to a significant overlap of Down's syndrome with the P2RY8-CRLF2 fusion gene, 20, 53 the number of children with Down's syndrome in our study is given for information purposes. alt, alteration; amp, amplification; del, deletion.
detected by MLPA is given in Supplementary Figure 2 . The frequency of IKZF1 deletion in our relapse patients is approximately twice as high as the frequency described in children with initial diagnosis of ALL (33 vs 14-19%) . 23, 25 This makes deletion of IKZF1 the second most frequent alteration in children with relapsed ALL after deletion of CDKN2A/2B. The increase of IKZF1 deletions at ALL relapse presumably results from the high relapse rate of these patients after primary treatment. [23] [24] [25] [26] [27] However, as IKZF1 deletions can also be acquired at relapse, 23, 37, 38 we assessed the copy number status of IKZF1 in matched samples from initial diagnosis in 49 out of the 68 patients with an IKZF1 deletion detected at relapse. We observed that the IKZF1 deletion emerged at relapse in approximately one fourth of the patients (12/49, 24%), thus contributing to the high frequency of this alteration in relapsed ALL (Supplementary Figure 3 and Supplementary Table 4 ). Together with our previous finding that TP53 alterations were acquired in half of the respective relapse patients, 32 these data strongly emphasise the need to re-analyse genetic alterations at the relapse stage of the disease before their use as prognostic factors in children with relapsed ALL.
In contrast to IKZF1 deletion, the P2RY8-CRLF2 fusion barely increased its frequency at relapse in our study, although it has also been associated with a higher rate of relapse after primary treatment on some ALL protocols (6.4 vs 4-5% at initial diagnosis). 22, 39, 40 Similar, the adverse prognostic factors BCR-ABL1 and MLL-AFF1 (refs 10,12,13) show no higher prevalence in our relapse cohort. In fact, the proportion of BCR-ABL1-positive relapse patients even decreased when compared with the earlier relapse trial ALL-REZ BFM 90 (2.5 vs 9.8%). 28 This likely reflects the amendments in primary treatment for BCR-ABL1-positive patients, for example, high-risk stratification, intensified treatment and more frequent transplantation in first continuous remission (CR1) from the early nineties onwards. 41 The comparatively low frequency of, for example, P2RY8-CRLF2, BCR-ABL1 and MLL-AFF1 in relapsed ALL (o10%) hampers a reasonable statistical analysis within our study, particularly if only subgroups of relapse patients are considered. Therefore, we focussed our further analysis on those genetic alterations present in more than 10% of relapse patients, that is, deletions of CDKN2A, CDKN2B, IKZF1, PAX5, ETV6, fusion gene ETV6-RUNX1 and alterations of TP53. Even so, statistical calculations on the alterations present in o10% of the relapse patients are given in the Supplementary Information.
Overlap of genetic alterations Several of the genetic alterations occurred simultaneously in the patients (Figure 1b) . Generally, the pattern of overlap in our relapse patients resembles that observed in children with initial diagnosis of ALL. 18, 25, 42, 43 More than 90% of relapse patients with a CDKN2A deletion also had a deletion of CDKN2B (Po0.001). 44 We therefore considered patients with a CDKN2A and/or CDKN2B deletion as one group (CDKN2A/2B) in all subsequent clinical analyses. Deletions of CDKN2A and CDKN2B also coincided significantly with deletions of PAX5 (P ¼ 0.001 and Po0.001) and IKZF1 (P ¼ 0.022 and P ¼ 0.032). 43, 45 Patients with an ETV6-RUNX1 fusion gene frequently showed an accompanying deletion of ETV6 (Po0.001), 46, 47 whereas the ETV6-RUNX1 rearrangement was mutually exclusive with IKZF1 deletions (Po0.001). 25, 43 Alterations of TP53 were not associated with any of the genetic alterations investigated.
Association of genetic alterations with clinical characteristics Next, we examined the correlation between the genetic alterations and clinical prognostic factors, risk group assignment and response to treatment. For genetic alterations present in 410% of relapse patients see Table 1 and for o10% of relapse patients see Supplementary Table 5 . As in previous ALL-REZ BFM trials, relapse patients with a CDKN2A/2B deletion frequently suffered a very early or early relapse (P ¼ 0.007), whereas nearly all ETV6-RUNX1-positive patients (29/31) presented with a late relapse after the completion of primary treatment (Po0.001). [29] [30] [31] Accordingly, patients with a CDKN2A/2B deletion were more often stratified into the high-risk group (P ¼ 0.054), whereas those having the ETV6-RUNX1 fusion gene were allocated to the intermediate-risk group (Po0.001). In contrast, the site of relapse did not correlate with any of the genetic alterations investigated. Regarding the response to treatment, patients with CDKN2A/2B deletion or with the ETV6-RUNX1 fusion gene more frequently achieved a second CR (P ¼ 0.045 and P ¼ 0.023, respectively), whereas alterations of TP53 were associated with a non-response to treatment as described previously (P ¼ 0.020). 32 On the level of MRD (in intermediate-risk patients), children having a CDKN2A/2B deletion also showed a trend towards a better response to treatment (P ¼ 0.057). In contrast, ETV6-RUNX1 and TP53 alteration were not associated with levels of MRD after induction therapy. For IKZF1, PAX5 and ETV6 deletion, we observed no correlation with clinical prognostic factors, risk group assignment or response to treatment at ALL relapse.
Association of genetic alterations with outcome
The outcome of relapse patients with different genetic alterations is summarised in Table 2 for alterations present in 410% of relapse patients (o10% see Supplementary Table 6 ). Deletions of IKZF1 had an adverse effect on the outcome of children with ALL relapse. Both pEFS and pOS were significantly decreased in patients with an IKZF1 deletion compared with IKZF1 non-deleted patients (pEFS: 0.30±0.06 vs 0.51±0.05, P ¼ 0.002; pOS: 0.36±0.07 vs 0.60±0.05, P ¼ 0.001; Table 2 and Figure 2a) . The most common event in relapse patients with an IKZF1 deletion was a subsequent relapse shown by an increased cumulative incidence of second relapse (CIR: 0.41±0.07 vs 0.23±0.04; P ¼ 0.006; Table 2 and Figure 2a) . Hence, the adverse effect of IKZF1 deletion on outcome of children with initial diagnosis of ALL [23] [24] [25] [26] [27] persists in children with relapsed ALL despite patients receiving an intensified relapse treatment.
Similar to patients with an IKZF1 deletion, children with a deletion of CDKN2A/2B had a significantly increased incidence of second relapse compared with CDKN2A/2B non-deleted patients (CIR: 0.40±0.06 vs 0.21±0.04; Po.001; Table 2 and Figure 2b) . However, as observed in previous ALL-REZ BFM trials, 31 there was no significantly different pEFS and pOS between patients with or without a CDKN2A/2B deletion (pEFS: 0.45±0.06 vs 0.43±0.05, P ¼ 0.990; pOS: 0.48 ± 0.07 vs 0.54 ± 0.05, P ¼ 0.443; Table 2 and Figure 2b ). In fact, patients with a CDKN2A/2B deletion more frequently achieved a second remission (Table 1) ; however, due to the high incidence of subsequent relapses, the pEFS of patients with CDKN2A/2B deletion ultimately was similar to the pEFS of patients without the deletion. This ambiguous result adds to the existing controversy on the prognostic value of CDKN2A/2B deletions (Sulong et al. 48 and references therein). It has been postulated earlier that the conflicting prognostic significance of CDKN2A/2B deletions might be caused by an overlap of this alteration with several distinct genetic subgroups of ALL. 48 This is in line with the significant overlap of CDKN2A/2B and IKZF1 deletions in our ALL relapse patients (Figure 1b ) that might contribute to the observed increased relapse rate in patients with CDKN2A/2B deletions. In contrast to CDKN2A/2B deletions, deletions of PAX5 were not associated with outcome after first relapse at all, although both genes are located on the short arm of chromosome 9. To clarify the different association of CDKN2A/2B and PAX5 alterations with outcome, we further separated the patients into three subgroups based on the MLPA data: (i) patients with a deletion of both loci (CDKN2A/2B and PAX5), (ii) patients with a CDKN2A/2B deletion only and (iii) patients with a PAX5 deletion only (Supplementary Table 7 ). The pEFS and pOS did not Genetics of relapsed childhood B-cell precursor ALL S Krentz et al 
All patients 204 (100) 121 (59) 83 (41) 136 (67) 68 (33) 150 (74) 54 (26) 153 (75) 51 (25) 173 (85) 31 (15) 181 (89) (23) 30 (22) 12 (18) 30 (20) 12 (22) 32 (21) 10 (20) 40 (23) 2 (7) 37 (20) 5 (22) Late 118 (58) 80 (66) 38 (46) 80 (59) 38 (56) 88 (59) 30 (56) 83 (54) 35 (69) 89 (51) 29 (94) 108 (60) (17) 22 (27) 30 (22) 12 (18) 28 (19) 14 (26) 30 (20) 12 (24) 33 (19) 9 (29) 39 (22) 3 (13) Relapse-risk group (62) 37 (73) 0.178 101 (58) 29 (94) o0.001 119 (66) 11 (48) (31) 37 (45) 48 (35) 26 (38) 54 (36) 20 (37) 60 (39) 14 (28) 72 (42) 2 (7) 62 (34) 12 (52) MRD (S2 only) (52) 15 (33) 31 (40) 21 (55) 40 (46) 12 (41) 36 (43) 16 (50) 41 (46) 11 (41) 47 (44) (24) 10 (12) 23 (17) 16 (24) 30 (20) 9 (17) 29 (19) 10 (20) 38 (22) 1 (3) 30 (17) 9 (39) Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; BM, bone marrow; CR2, second complete remission; MRD, minimal residual disease. Genetics of relapsed childhood B-cell precursor ALL S Krentz et al Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; CIR, cumulative incidence of relapse; pEFS, probability of event-free survival; pOS, probability of overall survival; s.e., standard error.
a Events: induction death, non-response to chemotherapy, secondary malignancy, second relapse, treatment-related death. Note: Table shows genetic alterations with a prevalence of more than 10% in the study cohort. Bold entries indicate statistically significant results (P-value o0.05).
years post relapse diagnosis cumulative incidence of relapse years post relapse diagnosis overall survival (probability) years post relapse diagnosis event-free survival (probability) Figure 2 . Survival analysis of patients by IKZF1 or CDKN2A/2B deletion. Probability of EFS (left), cumulative incidence of second relapse (CIR, middle) and probability of OS (right) of children with first relapse of BCP-ALL differentiated by IKZF1 deletion (IKZF1 del, a) and by CDKN2A and/or CDKN2B deletion (CDKN2A/2B del, b). cens, censored; del, deletion.
significantly differ among subgroups (P ¼ 0.629 and 0.811). In contrast, the incidence of a second relapse was higher in patients who had a deletion of at least CDKN2A/2B (groups (i) and (ii); P ¼ 0.002, Supplementary Table 7) . Interestingly, these two subgroups also showed an increased frequency of IKZF1 deletion (33% and 56%, respectively, versus 21% in group (iii)), which again indicates that IKZF1 deletion contributes to the higher relapse rates here. Together, these data underscore the notion that deletions of CDKN2A/2B or PAX5 frequently occur as accompanying alterations that might contribute to leukemogenesis but, however, are less relevant for resistance to chemotherapy or treatment failure.
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The ETV6-RUNX1 fusion gene was generally associated with a good prognosis in our study, that is, a high rate of second remission (Table 1 ) and a favourable pEFS and pOS (Table 2) , which is comparable to observations from previous ALL-REZ BFM trials. 29, 30 However, the outcome was worse if an accompanying deletion in the ETV6 gene was present. This deletion occurred in 52% of the ETV6-RUNX1-positive relapse patients (vs 20% in ETV6-RUNX1-negative patients, P ¼ 0.001) and was associated with a decreased pEFS (0.68 ± 0.12) compared with ETV6-RUNX1-positive patients lacking this extra deletion (1.00±0.00, P ¼ 0.020). Secondary ETV6 deletions have been associated with outcome in ETV6-RUNX1-positive ALL previously, but so far the prognostic effect of this deletion remains inconsistent (reviewed by event-free survival (probability) event-free survival (probability) event-free survival (probability) event-free survival (probability) event-free survival (probability) cumulative incidence of relapse Peter et al. 47 ). Like our observations, Attarbaschi et al. 49 showed that the outcome of patients with an accompanying deletion of ETV6 was inferior, whereas other studies found no prognostic correlation. 18, 46 However, the total number of ETV6-RUNX1-positive patients in our relapse study was limited and validation of the prognostic significance of the ETV6 deletion is required. Finally, alterations of the TP53 gene were highly correlated with an inferior pEFS and pOS (Po0.001 and P ¼ 0.030; Table 2 ) as already demonstrated in our previous report. 32 Multivariate Cox regression analysis We performed multivariate Cox regression analysis to assess the independence of the genetic alterations that were significantly associated with EFS in univariate analysis (IKZF1 deletion, ETV6-RUNX1 fusion gene and TP53 alteration) as well as the established clinical prognostic factors of ALL relapse (time to relapse and site of relapse). The Cox regression model identified time to relapse, deletion of IKZF1 and alteration of TP53 as the strongest predictive factors for an unfavourable pEFS ( Table 3) . As in previous ALL-REZ BFM reports, the ETV6-RUNX1 rearrangement did not remain in the model due to its strong association with the time of relapse, specifically with late relapse, and therefore cannot be regarded as independent prognostic factor. 30 Interestingly, in our study the established prognostic factor site of relapse, 4, 6, 7 that is, combined BM relapse versus isolated BM relapse, was also not maintained in our Cox regression model. ), IKZF1 deletion and TP53 alteration had no significant prognostic value. (c) We suggest to include IKZF1 and TP53 in a third stratification step following the established risk assessment of relapse patients by clinical and response-based factors. In the intermediate-risk (S2) group with low MRD, the presence of an IKZF1 deletion or TP53 alteration can identify patients with inferior prognosis. For these patients treatment intensification by, for example, HSCT may be considered as it is currently practiced for S2 patients with high MRD. In the high-risk (S3/S4) group, IKZF1 deletion is strongly predictive of a second relapse in children who achieved CR2 and received a HSCT. Therefore, these patients may be eligible for treatment intervention by experimental therapeutic strategies. alt, alteration; BCP, B-cell precursor; BM, bone marrow; cens, censored; CR2, 2nd complete remission; HSCT, hematopoietic stem cell transplantation; MRD, MRD at the end of induction therapy (week 5); pEFS, probability of event-free survival; wt, wild type. and high-risk (S3/S4) patients, as well as in further clinical and prognostic subgroups. In both the intermediate-risk and the highrisk group, deletions of IKZF1 and alterations of TP53 were associated with inferior outcome. This is shown for IKZF1 deletion in Figures 3a and b , whereas data on the effect of TP53 alteration in these subgroups were published earlier by us. 32 According to the ALL-REZ BFM 2002 protocol high-risk relapse patients who achieve a second CR after chemotherapy further receive a HSCT. In this subgroup of patients, IKZF1 deletion was particularly predictive for a second event identifying children with a pEFS as low as 9% (pEFS: 0.09±0.09 vs 0.57±0.10, P ¼ 0.001; Figure 3b ). Remarkably, these events were exclusively second relapses that occurred in less than 2 years post HSCT (CIR: 0.91 ± 0.11 vs 0.17 ± 0.08, Po0.001; Figure 3b ). Given this obviously very poor outcome with the current protocol treatment, IKZF1 deletion might represent a valuable novel marker to identify children with high-risk ALL relapse who are eligible for treatment intervention by experimental therapeutic strategies (Figure 4c ). So far, only MRD before HSCT has been established as reliable marker for outcome after allogeneic HSCT in CR2 (Bader et al. 50 and references therein). In a preliminary analysis, the prognostic value of IKZF1 deletion in high-risk relapse patients seemed to be independent from MRD before HSCT (data not shown); however, the number of children with available MRD data in this subgroup was small (n ¼ 22) and further validation is required. Interestingly, the association with poor outcome after HSCT was restricted to high-risk relapse patients as IKZF1 deletion did not predict a second relapse in intermediate-risk patients after allogeneic HSCT in CR2 (Supplementary Figure 4) . This differential effect of IKZF1 in intermediate-and high-risk relapse patients supports the idea that these groups might constitute two clinically and molecularly distinct entities. 4, 51, 52 Alterations of TP53 did not have any prognostic value for outcome post HSCT, neither in intermediate-risk nor in high-risk relapse patients (data not shown); however, the number of patients with TP53 alteration per subgroup were limited and larger studies are required.
IKZF1
In the intermediate-risk group, we found a particularly predictive value of IKZF1 deletion in those patients with low, but not with high MRD levels at the end of induction therapy (Figure 3a) . A similar limitation to MRD good responders has been observed in children with initial diagnosis of ALL, in whom a prognostic effect of IKZF1 deletion was described in patients with medium or low, but not in those with high MRD burden. 26 Regarding TP53, we observed the same differential effect in MRD stratified intermediate-risk patients. Alterations of TP53 were associated with poor outcome in intermediate-risk patients with low MRD (0.00 ± 0.00 vs 0.77 ± 0.06, Po0.001) but not in those with high MRD burden (0.60±0.22 vs 0.50±0.09, P ¼ 0.958). Again, the number of patients with TP53 alteration per subgroup was limited and validation is required.
Currently, intermediate-risk patients with low MRD level are considered to have a good prognosis with standard intensive consolidation and maintenance chemotherapy 8 and are therefore not allocated to HSCT in the current ALL-REZ BFM 2002 protocol. So far, no additional prognostic factors have been identified to stratify this group further and to indicate the requirement of treatment intensification. Therefore, it is noteworthy that the IKZF1 and TP53 status enables the distinction of subgroups with significantly different outcome here. Intermediate-risk relapse patients with low MRD and without deletion of IKZF1 or alteration of TP53 have a particular favourable pEFS of almost 90% after treatment with chemotherapy only (0.89±0.05, Po0.001, Figure 4a ). In contrast, intermediate-risk patients with low MRD levels but with an IKZF1 deletion or TP53 alteration achieved pEFS rates of merely 0.48 ± 0.014 and 0.00±0.00, respectively, and might therefore benefit from further treatment intensification. Hence, we suggest including IKZF1 deletion and TP53 alteration as prognostic factors in the risk assessment of children with ALL relapse in a third step following the established stratification by clinical markers and MRD response (Figure 4c) . We propose to investigate the IKZF1 and TP53 status in upcoming relapse trials to confirm our results on a prospective basis.
CONCLUSION
We show that of 13 genetic alterations that were investigated in our study, IKZF1 deletion and TP53 alteration had an independent prognostic significance in patients with relapsed pediatric BCP-ALL. Provided prospective validation, these genetic factors may be included in the risk assessment of children with ALL relapse to identify subgroups that require intensified and/or alternative treatment.
